Literature DB >> 24460937

Malignant melanoma and melanocortin 1 receptor.

A A Rosenkranz1, T A Slastnikova, M O Durymanov, A S Sobolev.   

Abstract

The conventional chemotherapeutic treatment of malignant melanoma still remains poorly efficient in most cases. Thus the use of specific features of these tumors for development of new therapeutic modalities is highly needed. Melanocortin 1 receptor (MC1R) overexpression on the cell surface of the vast majority of human melanomas, making MC1R a valuable marker of these tumors, is one of these features. Naturally, MC1R plays a key role in skin protection against damaging ultraviolet radiation by regulating eumelanin production. MC1R activation is involved in regulation of melanocyte cell division. This article reviews the peculiarities of regulation and expression of MC1R, melanocytes, and melanoma cells, along with the possible connection of MC1R with signaling pathways regulating proliferation of tumor cells. MC1R is a cell surface endocytic receptor, thus considered perspective for diagnostics and targeted drug delivery. A number of new therapeutic approaches that utilize MC1R, including endoradiotherapy with Auger electron and α- and β-particle emitters, photodynamic therapy, and gene therapy are now being developed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24460937      PMCID: PMC4064721          DOI: 10.1134/S0006297913110035

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  126 in total

1.  Enhancement of MSH receptor- and GAL4-mediated gene transfer by switching the nuclear import pathway.

Authors:  C K Chan; D A Jans
Journal:  Gene Ther       Date:  2001-01       Impact factor: 5.250

Review 2.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  Human melanoma targeting with alpha-MSH-melphalan conjugate.

Authors:  G E Ghanem; A Libert; R Arnould; A Vercammen; F Lejeune
Journal:  Melanoma Res       Date:  1991 Jun-Jul       Impact factor: 3.599

4.  A retro-inverso α-melanocyte stimulating hormone analog with MC1R-binding selectivity.

Authors:  Timothy Weeden; Jim Stefano; Su Duan; Andrea Edling; Lihui Hou; Wei-Lien Chuang; Michael A Perricone; Clark Pan; John L Dzuris
Journal:  J Pept Sci       Date:  2010-10-25       Impact factor: 1.905

5.  Melanotropin receptors demonstrated in situ in human melanoma.

Authors:  J B Tatro; M Atkins; J W Mier; S Hardarson; H Wolfe; T Smith; M L Entwistle; S Reichlin
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

6.  Regulation of melanocortin 1 receptor expression at the mRNA and protein levels by its natural agonist and antagonist.

Authors:  Francois Rouzaud; Jean-Philippe Annereau; Julio C Valencia; Gertrude-E Costin; Vincent J Hearing
Journal:  FASEB J       Date:  2003-09-18       Impact factor: 5.191

7.  Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide.

Authors:  Haixun Guo; Jianquan Yang; Fabio Gallazzi; Eric R Prossnitz; Larry A Sklar; Yubin Miao
Journal:  Bioconjug Chem       Date:  2009-11       Impact factor: 4.774

8.  Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.

Authors:  Zhen Cheng; Lan Zhang; Edward Graves; Zhengming Xiong; Mangal Dandekar; Xiaoyuan Chen; Sanjiv Sam Gambhir
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

9.  Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy.

Authors:  Jianquan Yang; Haixun Guo; Fabio Gallazzi; Marianne Berwick; R Steven Padilla; Yubin Miao
Journal:  Bioconjug Chem       Date:  2009-06-24       Impact factor: 4.774

10.  Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles.

Authors:  Luca Vannucci; Elisabetta Falvo; Manuela Fornara; Patrizio Di Micco; Oldrich Benada; Jiri Krizan; Jan Svoboda; Katarina Hulikova-Capkova; Veronica Morea; Alberto Boffi; Pierpaolo Ceci
Journal:  Int J Nanomedicine       Date:  2012-03-16
View more
  25 in total

Review 1.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 2.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

3.  A tumor-targeted immune checkpoint blocker.

Authors:  Yuhan Zhang; Changming Fang; Rongsheng E Wang; Ying Wang; Hui Guo; Chao Guo; Lijun Zhao; Shuhong Li; Xia Li; Peter G Schultz; Yu J Cao; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-22       Impact factor: 11.205

4.  Trigonal scaffolds for multivalent targeting of melanocortin receptors.

Authors:  N G R Dayan Elshan; Thanuja Jayasundera; Bobbi L Anglin; Craig S Weber; Ronald M Lynch; Eugene A Mash
Journal:  Org Biomol Chem       Date:  2015-02-14       Impact factor: 3.876

Review 5.  MC1R and melanin-based molecular probes for theranostic of melanoma and beyond.

Authors:  Hui Shi; Zhen Cheng
Journal:  Acta Pharmacol Sin       Date:  2022-08-25       Impact factor: 7.169

6.  Structural mechanism of calcium-mediated hormone recognition and Gβ interaction by the human melanocortin-1 receptor.

Authors:  Shanshan Ma; Yan Chen; Antao Dai; Wanchao Yin; Jia Guo; Dehua Yang; Fulai Zhou; Yi Jiang; Ming-Wei Wang; H Eric Xu
Journal:  Cell Res       Date:  2021-08-27       Impact factor: 46.297

7.  Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer.

Authors:  Dingli Song; Dai Zhang; Sisi Chen; Jie Wu; Qian Hao; Lili Zhao; Hong Ren; Ning Du
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

8.  Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.

Authors:  Wissam Beaino; Jessie R Nedrow; Carolyn J Anderson
Journal:  Mol Pharm       Date:  2015-05-08       Impact factor: 4.939

9.  Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging.

Authors:  Feng Chen; Xiuli Zhang; Kai Ma; Brian Madajewski; Miriam Benezra; Li Zhang; Evan Phillips; Melik Z Turker; Fabio Gallazzi; Oula Penate-Medina; Michael Overholtzer; Mohan Pauliah; Mithat Gonen; Pat Zanzonico; Ulrich Wiesner; Michelle S Bradbury; Thomas P Quinn
Journal:  ACS Appl Mater Interfaces       Date:  2018-01-24       Impact factor: 9.229

10.  Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.

Authors:  Mengshi Li; Dijie Liu; Dongyoul Lee; Somya Kapoor; Katherine N Gibson-Corley; Thomas P Quinn; Edwin A Sagastume; Sarah L Mott; Susan A Walsh; Michael R Acevedo; Frances L Johnson; Michael K Schultz
Journal:  Mol Pharm       Date:  2019-07-31       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.